Inflammation in Neuropsychiatric Disorders

Chapter One. Inflammation in Anxiety

1 Introduction

2 Cytokines, Brain, and Behavior

3 Inflammation in Anxiety Disorders

4 Inflammation in Anxiety Disorders: Potential Role of Oxidative Stress

5 Oxidative Stress, Transcription Factors, and Inflammation

6 Conclusion

Chapter Two. Inflammation-Related Disorders in the Tryptophan Catabolite Pathway in Depression and Somatization

1 Introduction

2 Tryptophan and the TRYCAT Pathway

3 The TRYCAT Pathway in Somatization

4 Activation of the TRYCAT Pathway May Cause Somatization

5 The TRYCAT Pathway, the CNS, and Somatization

6 Summary

7 Potential Treatment Implications

Chapter Three. Inflammation in Schizophrenia

1 Introduction

2 The Immune Response and the Type-1 and Type-2 Polarization

3 Inflammation in Schizophrenia

4 Type-1 and Type-2 Immune Response in Schizophrenia

5 Antipsychotic Drugs and the Type-1/Type-2 Imbalance in Schizophrenia

6 The Monocyte/Macrophage System in Schizophrenia

7 Brain Imaging and Microglia Activation in Schizophrenia

8 The Tryptophan–Kynurenine Metabolism in Schizophrenia

9 Treatment Options for Schizophrenia Based on Immune Modulation

10 COX-2 Inhibition as Therapeutic Approach in Schizophrenia

Chapter Four. Inflammation in Parkinson’s Disease

1 Introduction

2 Parkinson’s Disease

3 Inflammation in PD

4 Evidence of Inflammation in PD

5 Inflammation in Animal Models of PD

6 Molecular Mechanisms of Inflammation in PD

7 Therapeutic Implications

8 Conclusions

Chapter Five. Treatment with Aβ42 Binding d-Amino Acid Peptides Reduce Amyloid Deposition and Inflammation in APP/PS1 Double Transgenic Mice

1 Introduction

2 Materials and Methods

2.1 Animals

2.2 Peptides

2.3 Hippocampal infusion

2.4 Behavior

2.5 Histopathology